Reportable Segment Information

12 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Reportable Segment Information

14. Reportable Segment Information

Reportable segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We operate two reportable segments:

•Medical Device: Manufacture of performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary, and structural heart, among others; and the manufacture of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.

•In Vitro Diagnostics: Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Component products include protein stabilizers, substrates, surface coatings and antigens.

Segment revenue, operating income (loss), and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2023			2022			2021
Revenue:
Medical Device	$	105,783		$	72,389		$	78,253
In Vitro Diagnostics		26,801			27,562			26,883
Total revenue	$	132,584		$	99,951		$	105,136
Operating income (loss):
Medical Device	$	5,084		$	(22,923	)	$	4,683
In Vitro Diagnostics		12,637			13,073			13,770
Total segment operating income (loss)		17,721			(9,850	)		18,453
Corporate		(12,571	)		(12,247	)		(11,750	)
Total operating income (loss)	$	5,150		$	(22,097	)	$	6,703
Depreciation and amortization:
Medical Device	$	7,874		$	8,368		$	7,224
In Vitro Diagnostics		321			355			395
Corporate		327			419			398
Total depreciation and amortization	$	8,522		$	9,142		$	8,017

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2023		2022
U.S.	$	23,525	$	24,788
Ireland		28,707		30,505